Biodesix (NASDAQ:BDSX) vs. Aeon Global Health (OTCMKTS:AGHC) Head-To-Head Survey

Biodesix (NASDAQ:BDSX) and Aeon Global Health (OTCMKTS:AGHC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Profitability

This table compares Biodesix and Aeon Global Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodesix	-66.84%	-275.79%	-43.05%
Aeon Global Health	N/A	N/A	N/A

Valuation & Earnings

This table compares Biodesix and Aeon Global Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$49.09 million	3.41	-$52.15 million	($0.39)	-2.95
Aeon Global Health	N/A	N/A	N/A	N/A	N/A

Aeon Global Health has lower revenue, but higher earnings than Biodesix.

Analyst Ratings

This is a summary of recent ratings for Biodesix and Aeon Global Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	0	0	5	0	3.00
Aeon Global Health	0	0	0	0	0.00

Biodesix currently has a consensus price target of $3.06, indicating a potential upside of 166.09%. Given Biodesix’s stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Aeon Global Health.

Insider and Institutional Ownership

21.0% of Biodesix shares are held by institutional investors. 69.2% of Biodesix shares are held by insiders. Comparatively, 11.5% of Aeon Global Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biodesix beats Aeon Global Health on 6 of the 9 factors compared between the two stocks.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

About Aeon Global Health

AEON Global Health Corp. is a growth oriented provider of personalized, actionable medical informatics, and telemedicine. It offers a comprehensive menu of diagnostic and laboratory developed assays, as well as interpretive data for a range of inherited conditions. The company was founded by Hanif A. Roshan and Shawn Desai in August 1985 and is headquartered in Gainesville, GA.